Managing patients taking novel oral anticoagulants (NOAs) in dentistry: A discussion paper on clinical implications [PDF]
, 2016 Background The aim of this paper is to contribute to the discussion on how to approach patients taking new orally administered anticoagulants (NOAs) dabigatran etexilate (a direct thrombin inhibitor), rivaroxaban and apixaban (factor Xa inhibitors ...
Costantinides, Fulvia +3 more
core +1 more source
Case Reports in Critical Care, 2015 The oral anticoagulant dabigatran etexilate can be a challenge when patients need acute surgery. Sepsis and acute renal failure exacerbate the anticoagulant effect.
Rikke Ebenhard Højland +2 more
doaj +1 more source
Dabigatran versus Warfarin for the Treatment of Pediatric Thromboembolism: A Pilot Randomized Trial [PDF]
Pharmaceutical Sciences, 2020 Background: Venous thromboembolism (VTE) is still a problematic situation in children. Drugs like warfarin, enoxaparin, and heparin are current standard of care in childhood VTE. This study was designed to compare the efficacy of warfarin with dabigatran
Aziz Eghbali +5 more
doaj +1 more source
Impact of Pharmacists' audit on improving the quality of prescription of dabigatran etexilate methanesulfonate: a retrospective study. [PDF]
J Pharm Health Care Sci, 2017 Shimizu T +4 more
europepmc +3 more sources
Phase 3, single-arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design. [PDF]
Res Pract Thromb Haemost, 2018 Luciani M +14 more
europepmc +3 more sources
Role of new anticoagulants for the prevention of venous thromboembolism after major orthopaedic surgery and in hospitalised acutely ill medical patients. [PDF]
, 2012 SummaryAnticoagulation therapy for the prevention of venous thromboembolic events is indicated in patients after major orthopaedic surgery and in hospitalised acutely ill medical patients, who have a high or moderate risk of venous thromboembolism (VTE),
Ageno W, Spyropoulos AC, Turpie AG
core +1 more source
Pharmacometric Characterization of Dabigatran Hemodialysis [PDF]
, 2013 BACKGROUND: Hemodialysis has been shown to be a useful method of decreasing dabigatran plasma levels in situations that require rapid elimination of this thrombin inhibitor.
Alexander Staab +5 more
core +1 more source
New safety standards for anticoagulant therapy in the treatment of atrial fibrillation
Российский кардиологический журнал, 2018 The review article study the safety and efficacy of using direct acting oral anticoagulants: thrombin inhibitor dabigatran etexilate and inhibitors Xa of the blood clotting factor apixaban, rivaroxaban and edoxaban compared with the vitamin K antagonist ...
E. I. Baranova
doaj +1 more source
Российский кардиологический журнал, 2019 The review discusses the problem of patient-oriented choice of anticoagulants for nonvalvular atrial fibrillation (AF). The efficacy and safety profile of dabigatran etexilate and a group of patients with advantage of dabigatran application: patients ...
E. I. Baranova, Zhanna Kobalava
doaj +1 more source
Dabigatran etexilate for thromboprophylaxis in over 5000 hip or knee replacement patients in a real-world clinical setting [PDF]
, 2016 BACKGROUND: Thromboprophylaxis is recommended for patients undergoing total hip or total knee replacement (THR, TKR). An international, open-label, prospective, observational, single-arm study in a routine clinical setting was performed to assess the ...
Brueckmann, Martina +6 more
core +1 more source